Q2 2026 Relmada Therapeutics Inc Earnings Call Transcript

Aug 6, 2026 / 08:30 PM GMT

Release Date Price: $5.37 (-1.29%)

Transcript 8-K10-Q

Key Points

Positve

Relmada Therapeutics Inc (RLMD) reported strong phase 2 data for NDVO1, with 95% of patients achieving a complete response at any time and 76% having a durable complete response at 12 months.
The company has a strong balance sheet with $217.7 million in cash, expected to fund operations through 2029, including the completion of the phase 3 program for NDVO1.
Relmada Therapeutics Inc (RLMD) has FDA alignment on two planned registrational pathways for NDVO1, de-risking the regulatory path forward.
The company has a clear plan to file INDs for both NDVO1 and sopranolol by the end of 2026, with clinical trial sites already engaged and prepared to enroll patients.
The addition of a new Chief Business Officer with nearly three decades of experience in uro-oncology, including leading the US launch of the first FDA-approved intravesical gene therapy for NMIBC, strengthens the team's commercial and development expertise.

Negative

Relmada Therapeutics Inc (RLMD) has delayed the NDVO1 IND filing from mid-2026 to the end of 2026 due to manufacturing scale-up challenges, including scheduling with GMP manufacturing partners.
The company has not yet decided on the timing or format of initial phase 3 clinical data disclosure, with the 3-month complete response data potentially pushed into the first half of 2027.
Manufacturing for NDVO1 remains the final and critical gating factor, with the company needing to complete GMP batch production and stability data before filing the IND.
Relmada Therapeutics Inc (RLMD) has not yet reviewed the 18-month phase 2 data, as management has been entirely focused on phase 3 preparation, leaving a potential data gap for investors.
The company's net loss increased to $12.9 million in Q2 2026 from $9.9 million in Q2 2025, driven by higher R&D and manufacturing costs.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

RLMD.OQ - Relmada Therapeutics Inc
Q2 2026 Relmada Therapeutics Inc Earnings Call
Aug 06, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
1,

Good afternoon and welcome to Remada Therapeutics second quarter earnings conference call at this time, all participants are in a listen-only mode.

After the prepared remarks, we will conduct a question-and-answer session.

To ask a question, please press star 1.

As a reminder, this conference call is being recorded and will be available for replay on the Realmada website.

I would now like to turn the call over to Joyce Long again.

Please go ahead.

Thank you, operator.

Good day everyone, and thank you for joining us today.

This afternoon, Ramada issued a press release providing the business update and outlining its financial results for

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.